Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v16-EN | Version v5-FR | |
---|---|---|
Language | English | French |
Date Updated | 2021-03-19 | 2019-08-12 |
Drug Identification Number | 00799815 | 00799815 |
Brand name | DIANEAL PD 101 CAPD SOLUTION W 1.5% DEXTROSE | DIANEAL PD 101 CAPD SOLUTION W 1.5% DEXTROSE |
Common or Proper name | DIANEAL PD 101 CAPD SOLUTION W 1.5% DEXTROSE | DIANEAL PD 101 CAPD SOLUTION W 1.5% DEXTROSE |
Company Name | VANTIVE ULC | VANTIVE ULC |
Ingredients | SODIUM LACTATE DEXTROSE MAGNESIUM CHLORIDE CALCIUM CHLORIDE SODIUM CHLORIDE | SODIUM LACTATE DEXTROSE MAGNESIUM CHLORIDE CALCIUM CHLORIDE SODIUM CHLORIDE |
Strength(s) | 392MG 1.5G 15.2MG 23.9MG 567MG | 392MG 1.5G 15.2MG 23.9MG 567MG |
Dosage form(s) | LIQUID | LIQUID |
Route of administration | DIALYSIS | DIALYSIS |
Packaging size | 2.5L Twinbag | 2.5L Twinbag |
ATC code | B05ZA | B05ZA |
ATC description | HEMODIALYTICS AND HEMOFILTRATES | HEMODIALYTICS AND HEMOFILTRATES |
Reason for discontinuation | Business reasons | Business reasons |
Anticipated discontinuation date | 2021-03-18 | 2021-01-31 |
Actual discontinuation date | 2021-03-18 | |
Remaining supply date | 2021-03-18 | 2021-01-31 |
Discontinuation status | Discontinued | To be discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | Prescribers will have the option to make prescription adjustments to accommodate alternate fill offerings and assess suitability for APD. Patients requiring calcium supplementation can also obtain this through alternate routes such as the oral, IV or IP route. It is up to the healthcare professional to decide on the best dose and route of administration of calcium supplements for their patient. | Prescribers will have the option to make prescription adjustments to accommodate alternate fill offerings and assess suitability for APD. Patients requiring calcium supplementation can also obtain this through alternate routes such as the oral, IV or IP route. It is up to the healthcare professional to decide on the best dose and route of administration of calcium supplements for their patient. |
Health Canada comments |